BR112022027124A2 - Formulações para promover a hidratação e métodos de uso das mesmas - Google Patents

Formulações para promover a hidratação e métodos de uso das mesmas

Info

Publication number
BR112022027124A2
BR112022027124A2 BR112022027124A BR112022027124A BR112022027124A2 BR 112022027124 A2 BR112022027124 A2 BR 112022027124A2 BR 112022027124 A BR112022027124 A BR 112022027124A BR 112022027124 A BR112022027124 A BR 112022027124A BR 112022027124 A2 BR112022027124 A2 BR 112022027124A2
Authority
BR
Brazil
Prior art keywords
barrier function
intestinal barrier
formulations
hydration
methods
Prior art date
Application number
BR112022027124A
Other languages
English (en)
Portuguese (pt)
Inventor
Vidyasagar Sadasivan
Grosche Astrid
Xu Xiaodong
Lin Shanshan
Cheuvront Samuel
Kenefick Robert
Gatto Stephen
Original Assignee
Univ Florida
Entrinsic Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Florida, Entrinsic Llc filed Critical Univ Florida
Publication of BR112022027124A2 publication Critical patent/BR112022027124A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52Adding ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
BR112022027124A 2020-07-02 2021-07-01 Formulações para promover a hidratação e métodos de uso das mesmas BR112022027124A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063047300P 2020-07-02 2020-07-02
PCT/US2021/040090 WO2022006397A1 (en) 2020-07-02 2021-07-01 Formulations for promoting hydration and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022027124A2 true BR112022027124A2 (pt) 2023-03-07

Family

ID=79314908

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022027124A BR112022027124A2 (pt) 2020-07-02 2021-07-01 Formulações para promover a hidratação e métodos de uso das mesmas

Country Status (11)

Country Link
US (2) US12357600B2 (https=)
EP (1) EP4175662A4 (https=)
JP (1) JP2023533617A (https=)
KR (1) KR20230047371A (https=)
CN (1) CN116194136A (https=)
AU (1) AU2021300188A1 (https=)
BR (1) BR112022027124A2 (https=)
CA (1) CA3184691A1 (https=)
IL (1) IL299488A (https=)
MX (1) MX2023000004A (https=)
WO (1) WO2022006397A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11878073B1 (en) * 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3916903A1 (de) * 1989-05-24 1991-02-28 Leopold Pharma Gmbh Waessrige zusammensetzung fuer die parenterale ernaehrung
JP2002275059A (ja) * 2001-03-15 2002-09-25 Inst Of Physical & Chemical Res 腎機能障害改善用アミノ酸組成物
WO2010017403A2 (en) * 2008-08-06 2010-02-11 Immunopath Profile, Inc. Therapeutic compositions, devices and methods for observing treated tissues
JPWO2010041647A1 (ja) * 2008-10-06 2012-03-08 株式会社明治 アミノ酸組成物を有効成分として含む持久力向上剤、疲労防止剤、又は疲労回復剤
MX350541B (es) * 2010-09-24 2017-09-08 Univ Florida Materiales y metodos para mejorar la funcion gastrointestinal.
HK1204290A1 (en) * 2012-02-08 2015-11-13 University Of Florida Research Foundation, Inc. Materials and methods for treating diarrhea
MX2017006748A (es) * 2014-11-24 2017-08-28 Entrinsic Health Solutions Inc Composiciones de aminoácidos para el tratamiento de síntomas de enfermedades.
CN115645388B (zh) * 2016-10-04 2024-12-10 佛罗里达大学研究基金会公司 氨基酸组合物及其用途
CN109218470B (zh) * 2017-07-05 2021-08-24 中兴通讯股份有限公司 移动终端及其控制方法
WO2019070753A1 (en) * 2017-10-02 2019-04-11 University Of Florida Research Foundation, Incorporated AMINO ACID COMPOSITIONS AND METHODS FOR TREATING DIARRHEA

Also Published As

Publication number Publication date
IL299488A (en) 2023-02-01
JP2023533617A (ja) 2023-08-03
AU2021300188A1 (en) 2023-02-02
MX2023000004A (es) 2023-03-06
US12357600B2 (en) 2025-07-15
KR20230047371A (ko) 2023-04-07
US20230149335A1 (en) 2023-05-18
CN116194136A (zh) 2023-05-30
WO2022006397A1 (en) 2022-01-06
CA3184691A1 (en) 2022-12-30
EP4175662A4 (en) 2024-07-17
EP4175662A1 (en) 2023-05-10
US20250367154A1 (en) 2025-12-04

Similar Documents

Publication Publication Date Title
Dréno What is new in the pathophysiology of acne, an overview
Pang et al. The effect of trans-resveratrol on post-stroke depression via regulation of hypothalamus–pituitary–adrenal axis
Gunepin et al. Impact of chronic stress on periodontal health
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112018017031A2 (pt) formulações de antagonista de il-6 e usos das mesmas
UY29377A1 (es) Nuevas formilaciones líquidas de rotavirus, su preparación y sus usos.
BRPI0607326A2 (pt) composição de vacina, variante de peptìdeo de survivina, uso da referida composição, kit em partes e medicamento
Alcocer‐Gómez et al. Effect of coenzyme Q10 on psychopathological symptoms in fibromyalgia patients
Greenspan et al. Catecholamine metabolism in affective disorders: II. Norepinephrine, normetanephrine, epinephrine, metanephrine, and VMA excretion in hypomanic patients
BRPI0514236A (pt) composto, uso do mesmo, composição farmacêutica, e, métodos para produzir 17-desmetilrapamicina ou um análogo da mesma, para gerar uma cepa recombinante, para preparar um análogo de 17-desmetilrapamicina e para gerar um análogo de 17-desmetilrapamicina
BRPI0415315A (pt) métodos de aumentar uma resposta imune a um antìgeno em um mamìfero, e de reduzir a severidade de um cáncer em um paciente, preparação combinada, kit farmacêutico, e, usos de um polipeptìdeo de il-18 ou seu fragmento ou derivado bioativos, e de uma composição imunogênica
ECSP22086300A (es) Composiciones que comprenden nanopartículas, método de elaboración y usos de las mismas
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
EP4477267A3 (en) Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds
Pengfei et al. Possible mechanism underlying analgesic effect of Tuina in rats may involve piezo mechanosensitive channels within dorsal root ganglia axon
EP4552693A3 (en) Collagen peptide-based medicament compositions and devices and methods of production and use thereof
BR112023019488A2 (pt) Colágeno tipo ii recombinante para uso terapêutico
BR112022016010A2 (pt) Formulações de anticorpos anti-tslp humanos e métodos de tratamento de doenças inflamatórias
Kulbida et al. Beneficial effects of hirudotherapy in a chronic case of complex regional pain syndrome
BR112022027124A2 (pt) Formulações para promover a hidratação e métodos de uso das mesmas
BR112023001121A2 (pt) Cepa c de prevotella histicola como uma terapia oral para doenças inflamatórias
Marano et al. Vipera aspis bite neurotoxicity: two pediatric cases in Central Italy
MX2023010918A (es) Metodos y composiciones para el tratamiento de enfermedades oculares.
CL2025001428A1 (es) Composiciones farmacéuticas para administración ocular
MX2014004362A (es) Preparado de huevo con propiedades regeneradoras, analgesicas y/o anti-inflamatorias.